Picton Mahoney Asset Management Boosts Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Picton Mahoney Asset Management increased its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6,600.0% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,608 shares of the company’s stock after buying an additional 1,584 shares during the period. Picton Mahoney Asset Management’s holdings in Amphastar Pharmaceuticals were worth $46,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Signaturefd LLC boosted its stake in Amphastar Pharmaceuticals by 147.7% during the 1st quarter. Signaturefd LLC now owns 872 shares of the company’s stock valued at $25,000 after purchasing an additional 520 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Amphastar Pharmaceuticals during the 4th quarter valued at $38,000. Tower Research Capital LLC TRC lifted its holdings in shares of Amphastar Pharmaceuticals by 43.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,145 shares of the company’s stock valued at $43,000 after buying an additional 348 shares during the period. IFP Advisors Inc bought a new position in shares of Amphastar Pharmaceuticals during the 1st quarter valued at $34,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 46.6% during the 1st quarter. GAMMA Investing LLC now owns 1,333 shares of the company’s stock valued at $39,000 after buying an additional 424 shares during the period. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Trading Down 1.8%

AMPH opened at $20.95 on Friday. The firm has a market cap of $987.58 million, a P/E ratio of 7.59 and a beta of 0.72. Amphastar Pharmaceuticals, Inc. has a 12 month low of $20.43 and a 12 month high of $53.96. The company has a current ratio of 2.95, a quick ratio of 2.02 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average of $23.84 and a 200 day moving average of $27.00.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on AMPH shares. JPMorgan Chase & Co. reissued a “neutral” rating and set a $30.00 price target (down from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Finally, Wells Fargo & Company lowered their price target on Amphastar Pharmaceuticals from $40.00 to $35.00 and set an “overweight” rating on the stock in a report on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $32.33.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.